|
Sewak, Sanjeev; Sorich, Joan; O'Leary, James (2006) Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen. Anticancer Drugs 17:571-9
|
|
O'Leary, J J; Shapiro, R L; Ren, C J et al. (1999) Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 5:181-7
|
|
Wall, M E; Wani, M C (1996) Camptothecin. Discovery to clinic. Ann N Y Acad Sci 803:1-12
|
|
Potmesil, M; Arbuck, S G; Takimoto, C H et al. (1996) 9-Aminocamptothecin and beyond. Preclinical and clinical studies. Ann N Y Acad Sci 803:231-46
|
|
D'Arpa, P; Liu, L F (1995) Cell cycle-specific and transcription-related phosphorylation of mammalian topoisomerase I. Exp Cell Res 217:125-31
|
|
Newcomb, E W; Thomas, A; Selkirk, A et al. (1995) Frequent homozygous deletions of D13S218 on 13q14 in B-cell chronic lymphocytic leukemia independent of disease stage and retinoblastoma gene inactivation. Cancer Res 55:2044-7
|
|
Bodley, A L; Wani, M C; Wall, M E et al. (1995) Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations. Biochem Pharmacol 50:937-42
|
|
Potmesil, M; Vardeman, D; Kozielski, A J et al. (1995) Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res 55:5637-41
|
|
Pantazis, P; Kozielski, A; Rodriguez, R et al. (1994) Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts. Melanoma Res 4:5-10
|
|
Potmesil, M (1994) Camptothecins: from bench research to hospital wards. Cancer Res 54:1431-9
|
Showing the most recent 10 out of 17 publications
